American Trust’s GoodRx Holdings GDRX Stock Holding History

American Trust’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,350	Closed	-$239K	–	475
2022 Q1	$239K	Buy	+12,350	New	+$283K	0.02%	409

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSCM

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

American Trust's GDRX Position: Q2 2022 in Review

American Trust sold out of GoodRx Holdings (GDRX) in Q2 2022, closing a stake of 12,350 shares — an estimated $239K sold.

American Trust first reported a position in GDRX in Q1 2022 and held it in 1 quarter. The position peaked at $239K in Q1 2022. 174 funds tracked by Wall St. Rank hold GDRX as of Q2 2022.

American Trust reported no remaining GoodRx Holdings position as of Q2 2022 after selling out during the quarter.
American Trust sold 12,350 GoodRx Holdings shares in Q2 2022, an estimated $239K.
American Trust first reported a position in GoodRx Holdings in Q1 2022 and held it in 1 quarter.
American Trust's GoodRx Holdings position peaked at $239K in Q1 2022.
174 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2022.

Based on American Trust's 13F filing for Q2 2022, filed 3 Oct 2022.